Compare NRK & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRK | TBPH |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 914.2M | 824.9M |
| IPO Year | 2002 | 2013 |
| Metric | NRK | TBPH |
|---|---|---|
| Price | $10.53 | $16.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.40 |
| AVG Volume (30 Days) | 246.2K | ★ 402.7K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | N/A | ★ 2.06 |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | N/A | $8.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.15 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.30 | $8.33 |
| 52 Week High | $10.60 | $21.03 |
| Indicator | NRK | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 58.77 | 58.21 |
| Support Level | $10.38 | $13.41 |
| Resistance Level | $10.60 | $17.24 |
| Average True Range (ATR) | 0.07 | 0.41 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 70.73 | 64.71 |
Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.